GlassScriptPhysician profile
Kevin G Gray
NPI 1952528077
$7,249.19
in general payments reported to CMS, 2019-2025
31 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $1,051 · 2021: $914 · 2022: $958 · 2023: $918 · 2024: $1,157 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,337.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,460.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $882.68 | 2019-2025 | |
| Amgen INC. | $716.69 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $610.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $312.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.75 | 2019-2023 | Tradjenta, Synjardy |
| Kowa Pharmaceuticals America, INC. | $272.86 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $221.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $216.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $196.41 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Sanofi-Aventis U.S. LLC | $182.94 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.26 | 2024-2025 | Caplyta |
| Abbott Laboratories | $110.58 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.70 | 2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $84.08 | 2024-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.23 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.24 | 2020-2021 | |
| Astellas Pharma US INC | $60.15 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $55.69 | 2022-2023 | |
| Amarin Pharma, INC. | $40.31 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $29.74 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $29.37 | 2021-2022 | |
| Antares Pharma, INC. | $21.95 | 2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $21.95 | 2025 | Gvoke Hypopen |
| Nevro Corp. | $18.06 | 2023 | Senza |
| Alexion Pharmaceuticals, INC. | $17.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.77 | 2020 | |
| Genentech USA, INC. | $15.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.40 | 2024 | Quviviq |
| Allergan, INC. | $12.95 | 2020 | |
| Dexcom, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.